Beating EATL - towards rationally targeted therapy for enteropathy-associated T-cell lymphoma

Recruiting

Conditions: enteropathy-associated T-cell lymphoma
gluten intolerance
10025321
10025477

Registration Number: NL-OMON55365

Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 100

Inclusion Criteria

- * 18 years old
- Indication for a biopsy for the diagnosis or monitoring of:
non-CD / non-inflamed, CD / non-inflamed, active CD, pre-EATL, EATL
- Given informed consent

Exclusion Criteria

- No informed consent
- Insufficient knowledge of Dutch language and/or inability to understand the
information provided.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>It is currently unclear how the signalling pathways set off by TNF, IL-2 and<br /><br>IL-21 synergize to promote lymphoma growth. This project*s first goal is<br /><br>therefore to identify key signalling pathways activated by these cytokines and<br /><br>small-molecule inhibitors targeting these pathways. The efficacy of such<br /><br>inhibitors will be tested ex vivo using patient biopsies. This will allow a<br /><br>rational selection of drugs for future clinical trials, in which the predictive<br /><br>value of this ex vivo assay will also be evaluated.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Single-cell CyTOF:<br /><br>1. Explore heterogeneity of the immune system between RCDII patients<br /><br>2. Track the transition of the immune system in patients with celiac disease to<br /><br>patients with RCDII.<br /><br><br /><br>Imaging CyTOF:<br /><br>1. Validation of interesting immune cell subsets identified in single cell CyTOF<br /><br>2. Look at immune cell composition in patients with CeD/RCDII.<br /><br><br /><br>Single-cell RNA sequencing:<br /><br>1. Explore heterogeneity of gene expression between patients with RCDII.<br /><br><br /><br>FACS (sort), culture, cytotoxicity assays:<br /><br>1. Functionality assays on immune cell subsets found to be specific for<br /><br>CeD/RCDII. </p><br>